MedTrace Logo

Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer

NCT01380912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2011-06-27

No results posted yet for this study

Summary

A randomised double-blinded study, in which the patients either get methylprednisoloneacetate or saline solution in the mastectomy cavity to evaluate the efficacy of methylprednisoloneacetate in preventing seroma in patients operated for primary breast cancer.

Conditions

Interventions

DRUG

methylprednisoloneacetate

Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    collaborator OTHER

  • Copenhagen University Hospital at Herlev

    lead OTHER

Principal Investigators

  • Gro M Qvamme, MD

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380912 on ClinicalTrials.gov